HF 2508

1st Unofficial Engrossment - 87th Legislature (2011 - 2012) Posted on 04/03/2012 03:21pm

1.1A bill for an act

1.2relating to public safety; aligning state-controlled substance schedules with
1.3federal controlled substance schedules; modifying the authority of the Board of
1.4Pharmacy to regulate controlled substances; providing for penalties;amending Minnesota Statutes 2010, sections 152.02, as amended; 152.18, subdivision 1; Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6.1.7BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.8    Section 1. Minnesota Statutes 2010, section 152.02, as amended by Laws 2011, chapter
1.953, sections 4 and 5, is amended to read:
1.10152.02 SCHEDULES OF CONTROLLED SUBSTANCES;
1.11ADMINISTRATION OF CHAPTER.
1.12    Subdivision 1. Five schedules. There are established five schedules of controlled
1.13substances, to be known as Schedules I, II, III, IV, and V. Such The schedules shall
1.14initially consist of the substances listed in this section by whatever official name, common
1.15or usual name, chemical name, or trade name designated.
1.16    Subd. 2. Schedule I. The following items are listed in Schedule I: (a) Schedule I
1.17consists of the substances listed in this subdivision.
1.18(1) (b) Opiates. Unless specifically excepted or unless listed in another schedule,
1.19any of the following substances, including their analogs, isomers, esters, ethers, salts, and
1.20salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence
1.21of the analogs, isomers, esters, ethers and salts is possible within the specific chemical
1.22designation:
1.23(1) acetylmethadol;
1.24(2) allylprodine;
2.1(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
2.2levomethadyl acetate);
2.3(4) alphameprodine;
2.4(5) alphamethadol;
2.5(6) alpha-methylfentanyl benzethidine;
2.6(7) betacetylmethadol;
2.7(8) betameprodine;
2.8(9) betamethadol;
2.9(10) betaprodine;
2.10(11) clonitazene;
2.11(12) dextromoramide; dextrorphan;
2.12(13) diampromide;
2.13(14) diethyliambutene;
2.14(15) difenoxin;
2.15(16) dimenoxadol;
2.16(17) dimepheptanol;
2.17(18) dimethyliambutene;
2.18(19) dioxaphetyl butyrate;
2.19(20) dipipanone;
2.20(21) ethylmethylthiambutene;
2.21(22) etonitazene;
2.22(23) etoxeridine;
2.23(24) furethidine;
2.24(25) hydroxypethidine;
2.25(26) ketobemidone;
2.26(27) levomoramide;
2.27(28) levophenacylmorphan;
2.28(29) 3-methylfentanyl;
2.29(30) acetyl-alpha-methylfentanyl;
2.30(31) alpha-methylthiofentanyl;
2.31(32) benzylfentanyl beta-hydroxyfentanyl;
2.32(33) beta-hydroxy-3-methylfentanyl;
2.33(34) 3-methylthiofentanyl;
2.34(35) thenylfentanyl;
2.35(36) thiofentanyl;
2.36(37) para-fluorofentanyl;
3.1(38) morpheridine;
3.2(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.3(40) noracymethadol;
3.4(41) norlevorphanol;
3.5(42) normethadone;
3.6(43) norpipanone;
3.7(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.8(45) phenadoxone;
3.9(46) phenampromide;
3.10(47) phenomorphan;
3.11(48) phenoperidine;
3.12(49) piritramide;
3.13(50) proheptazine;
3.14(51) properidine;
3.15(52) propiram;
3.16(53) racemoramide;
3.17(54) tilidine;
3.18(55) trimeperidine.
3.19(2) (c) Opium derivatives. Any of the following opium derivatives substances,
3.20their analogs, salts, isomers, and salts of isomers, unless specifically excepted or unless
3.21listed in another schedule, whenever the existence of the analogs, salts, isomers and salts
3.22of isomers is possible within the specific chemical designation:
3.23(1) acetorphine;
3.24(2) acetyldihydrocodeine; acetylcodone;
3.25(3) benzylmorphine;
3.26(4) codeine methylbromide;
3.27(5) codeine-n-oxide;
3.28(6) cyprenorphine;
3.29(7) desomorphine;
3.30(8) dihydromorphine;
3.31(9) drotebanol;
3.32(10) etorphine;
3.33(11) heroin;
3.34(12) hydromorphinol;
3.35(13) methyldesorphine; methylhydromorphine
3.36(14) methyldihydromorphine;
4.1(15) morphine methylbromide;
4.2(16) morphine methylsulfonate;
4.3(17) morphine-n-oxide;
4.4(18) myrophine;
4.5(19) nicocodeine;
4.6(20) nicomorphine;
4.7(21) normorphine;
4.8(22) pholcodine;
4.9(23) thebacon.
4.10(3) (d) Hallucinogens. Any material, compound, mixture or preparation which
4.11contains any quantity of the following hallucinogenic substances, their analogs, salts,
4.12isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically
4.13excepted or unless listed in another schedule, whenever the existence of the analogs, salts,
4.14isomers, and salts of isomers is possible:
4.153,4-methylenedioxy amphetamine (1) methylenedioxy amphetamine;
4.163,4-methylenedioxymethamphetamine (2) methylenedioxymethamphetamine;
4.17(3) methylenedioxy-N-ethylamphetamine (MDEA);
4.18(4) n-hydroxy-methylenedioxyamphetamine;
4.19(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
4.20(6) 2,5-dimethoxyamphetamine (2,5-DMA);
4.21(7) 4-methoxyamphetamine;
4.22(8) 5-methoxy-3, 4-methylenedioxy amphetamine;
4.23(9) alpha-ethyltryptamine;
4.24(10) bufotenine;
4.25(11) diethyltryptamine;
4.26(12) dimethyltryptamine;
4.27(13) 3,4,5-trimethoxy amphetamine;
4.28(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
4.29(15) ibogaine;
4.30(16) lysergic acid diethylamide (LSD); marijuana;
4.31(17) mescaline;
4.32(18) parahexyl;
4.33(19) N-ethyl-3-piperidyl benzilate;
4.34(20) N-methyl-3-piperidyl benzilate;
4.35(21) psilocybin;
4.36(22) psilocyn;
5.1Tetrahydrocannabinols; 1-(1-(2-thienyl) cyclohexyl) piperidine (23) tenocyclidine
5.2(TPCP or TCP);
5.3(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
5.4(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
5.5(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
5.6(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
5.7(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
5.8(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
5.9(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
5.10(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
5.11(32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD);
5.122,5-dimethoxy-4-ethylphenethylamine, also known as (33)
5.134-ethyl-2,5-dimethoxyphenethylamine (2C-E);
5.142,5-dimethoxy-4-iodophenethylamine, also known as (34)
5.154-iodo-2,5-dimethoxyphenethylamine (2C-I);
5.16(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
5.17(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
5.18(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
5.19(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
5.20(2-CB-FLY);
5.21(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
5.22(40) alpha-methyltryptamine (AMT);
5.23(41) N,N-diisopropyltryptamine (DiPT);
5.24(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
5.25(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
5.26(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
5.27(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
5.28(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
5.29(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
5.30(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
5.31(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
5.32(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
5.33(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
5.34(52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
5.35(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
5.36(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
6.1(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
6.2(56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT);
6.3(57) methoxetamine (MXE);
6.4(58) 5-iodo-2-aminoindane (5-IAI);
6.5(59) 5,6-methylenedioxy-2-aminoindane (MDAI).
6.6(4) (e) Peyote, providing. All parts of the plant presently classified botanically as
6.7Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract
6.8from any part of the plant, and every compound, manufacture, salts, derivative, mixture,
6.9or preparation of the plant, its seeds or extracts. The listing of peyote as a controlled
6.10substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious
6.11ceremonies of the American Indian Church, and members of the American Indian Church
6.12are exempt from registration. Any person who manufactures peyote for or distributes
6.13peyote to the American Indian Church, however, is required to obtain federal registration
6.14annually and to comply with all other requirements of law.
6.15(5) (f) Central nervous system depressants. Unless specifically excepted or unless
6.16listed in another schedule, any material compound, mixture, or preparation which contains
6.17any quantity of the following substances having a depressant effect on the central nervous
6.18system, including its, their analogs, salts, isomers, and salts of isomers whenever the
6.19existence of the analogs, salts, isomers, and salts of isomers is possible within the specific
6.20chemical designation:
6.21(1) mecloqualone;
6.22(2) methaqualone;
6.23(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
6.24(4) flunitrazepam.
6.25(6) (g) Stimulants. Unless specifically excepted or unless listed in another schedule,
6.26any material compound, mixture, or preparation which contains any quantity of the
6.27following substances having a stimulant effect on the central nervous system, including its,
6.28their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs,
6.29salts, isomers, and salts of isomers is possible within the specific chemical designation:
6.30    (1) aminorex;
6.31(2) cathinone;
6.32(3) fenethylline;
6.33    (4) methcathinone;
6.34(5) methylaminorex;
6.35(6) N,N-dimethylamphetamine;
6.36(7) N-benzylpiperazine (BZP);
7.14-methylmethcathinone (8) methylmethcathinone (mephedrone);
7.2(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
7.34-methoxymethcathinone (10) methoxymethcathinone (methedrone);
7.43,4 - methylenedioxypyrovalerone (11) methylenedioxypyrovalerone (MDPV);
7.5(12) fluoromethcathinone;
7.6(13) methylethcathinone (MEC);
7.7(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
7.8(15) dimethylmethcathinone (DMMC);
7.9(16) fluoroamphetamine;
7.10(17) fluoromethamphetamine;
7.11(18) α-methylaminobutyrophenone (MABP or buphedrone);
7.12(19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone);
7.13(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
7.14(21) naphthylpyrovalerone (naphyrone);
7.15(22) and any other substance, except bupropion or compounds listed under a
7.16different schedule, that is structurally derived from 2-aminopropan-1-one by substitution
7.17at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not
7.18the compound is further modified in any of the following ways:
7.19(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
7.20haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
7.21system by one or more other univalent substituents;
7.22(ii) by substitution at the 3-position with an acyclic alkyl substituent;
7.23(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
7.24methoxybenzyl groups; or
7.25(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
7.26(7) (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless
7.27specifically excepted or unless listed in another schedule, any natural or synthetic material,
7.28compound, mixture, or preparation that contains any quantity of a substance that is a
7.29cannabinoid receptor agonist, including, but not limited to, the following substances and,
7.30their analogs, including isomers, whether optical, positional, or geometric; esters;, ethers;,
7.31salts;, and salts of isomers, esters, and ethers, whenever the existence of the isomers,
7.32esters, ethers, or salts is possible within the specific chemical designation:
7.331-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
7.34(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015),
7.351-Pentyl-3-(1-naphthoyl)indole (JWH-018), 1-hexyl-3-(naphthalen-1-oyl)indole
7.36(JWH-019), 1-Butyl-3-(1-naphthoyl)indole (JWH-073),
8.14-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-081),
8.24-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone
8.3(JWH-098), (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone
8.4(JWH-200), 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone
8.5(JWH-164), 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-203),
8.64-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210),
8.72-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250),
8.81-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), (6aR,10aR)-
8.99-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
8.10tetrahydrobenzo[c]chromen-1-ol (HU-210), (R)-(+)-[2,3-Dihydro-5-methyl-3-
8.11(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone
8.12(WIN-55,212-2), 2-[3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol (CP47,497),
8.13dimethylheptylpyran.
8.14(1) marijuana;
8.15(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis,
8.16synthetic equivalents of the substances contained in the cannabis plant or in the
8.17resinous extractives of the plant, or synthetic substances with similar chemical structure
8.18and pharmacological activity to those substances contained in the plant or resinous
8.19extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
8.20tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
8.21(3) synthetic cannabinoids, including the following substances:
8.22(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
8.23structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
8.24alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
8.252-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
8.26extent and whether or not substituted in the naphthyl ring to any extent. Examples of
8.27naphthoylindoles include, but are not limited to:
8.28(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
8.29(B) 1-Butul-3-(1-naphthoyl)indole (JWH-073);
8.30(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
8.31(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
8.32(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
8.33(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
8.34(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
8.35(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
8.36(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
9.1(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
9.2(ii) Napthylmethylindoles, which are any compounds containing a
9.31H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
9.4of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.51-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
9.6substituted in the indole ring to any extent and whether or not substituted in the naphthyl
9.7ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
9.8(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
9.9(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184).
9.10(iii) Naphthoylpyrroles, which are any compounds containing a
9.113-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
9.12pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.131-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
9.14further substituted in the pyrrole ring to any extent, whether or not substituted in the
9.15naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to,
9.16(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
9.17(iv) Naphthylmethylindenes, which are any compounds containing a
9.18naphthylideneindene structure with substitution at the 3-position of the indene
9.19ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.201-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
9.21substituted in the indene ring to any extent, whether or not substituted in the naphthyl
9.22ring to any extent. Examples of naphthylemethylindenes include, but are not limited to,
9.23E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
9.24(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
9.25structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
9.26alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
9.272-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
9.28any extent, whether or not substituted in the phenyl ring to any extent. Examples of
9.29phenylacetylindoles include, but are not limited to:
9.30(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
9.31(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
9.32(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
9.33(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
9.34(vi) Cyclohexylphenols, which are compounds containing a
9.352-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position
9.36of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
10.11-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
10.2substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
10.3but are not limited to:
10.4(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
10.5(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
10.6(Cannabicyclohexanol or CP 47,497 C8 homologue);
10.7(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
10.8-phenol (CP 55,940).
10.9(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
10.10structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
10.11alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
10.122-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
10.13any extent and whether or not substituted in the phenyl ring to any extent. Examples of
10.14benzoylindoles include, but are not limited to:
10.15(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
10.16(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
10.17(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
10.18(WIN 48,098 or Pravadoline).
10.19(viii) Others specifically named:
10.20(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.21-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
10.22(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
10.23-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
10.24(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
10.25-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).
10.26(8) (i) A controlled substance analog, to the extent that it is implicitly or explicitly
10.27intended for human consumption.
10.28    Subd. 3. Schedule II. The following items are listed in (a) Schedule II: consists of
10.29the substances listed in this subdivision.
10.30(1) (b) Unless specifically excepted or unless listed in another schedule, any of
10.31the following substances whether produced directly or indirectly by extraction from
10.32substances of vegetable origin or independently by means of chemical synthesis, or by a
10.33combination of extraction and chemical synthesis:
10.34(a) (1) Opium and opiate, and any salt, compound, derivative, or preparation
10.35of opium or opiate, including the following: raw opium, opium extracts, opium
10.36fluid extracts, powdered opium, granulated opium, tincture of opium, apomorphine,
11.1codeine, ethylmorphine, hydrocodone, hydromorphone, metopon, morphine, oxycodone,
11.2oxymorphone, thebaine.
11.3(i) Excluding:
11.4(A) apomorphine;
11.5(B) thebaine-derived butorphanol;
11.6(C) dextrophan;
11.7(D) nalbuphine;
11.8(E) nalmefene;
11.9(F) naloxone;
11.10(G) naltrexone;
11.11(H) and their respective salts;
11.12(ii) but including the following:
11.13(A) opium, in all forms and extracts;
11.14(B) codeine;
11.15(C) dihydroetorphine;
11.16(D) ethylmorphine;
11.17(E) etorphine hydrochloride;
11.18(F) hydrocodone;
11.19(G) hydromorphone;
11.20(H) metopon;
11.21(I) morphine;
11.22(J) oxycodone;
11.23(K) oxymorphone;
11.24(L) thebaine;
11.25(M) oripavine;
11.26(b) (2) any salt, compound, derivative, or preparation thereof which is chemically
11.27equivalent or identical with any of the substances referred to in clause (a) (1), except that
11.28these substances shall not include the isoquinoline alkaloids of opium.;
11.29(c) (3) opium poppy and poppy straw.;
11.30(d) (4) coca leaves and any salt, cocaine compound, derivative, or preparation
11.31of coca leaves, including cocaine and ecgonine, the salts and isomers of cocaine and
11.32ecgonine, and the salts of their isomers. (including cocaine and ecgonine and their salts,
11.33isomers, derivatives, and salts of isomers and derivatives), and any salt, compound,
11.34derivative, or preparation thereof which is chemically equivalent or identical with any of
11.35these substances, except that the substances shall not include decocainized coca leaves or
11.36extraction of coca leaves, which extractions do not contain cocaine or ecgonine;
12.1(e) Any salt, compound, derivative, or preparation thereof which is chemically
12.2equivalent or identical with any of the substances referred to in clause (d), except that
12.3the substances shall not include decocainized coca leaves or extraction of coca leaves,
12.4which extractions do not contain cocaine or ecgonine. (5) concentrate of poppy straw (the
12.5crude extract of poppy straw in either liquid, solid, or powder form which contains the
12.6phenanthrene alkaloids of the opium poppy).
12.7(2) (c) Any of the following opiates, including their isomers, esters, ethers, salts, and
12.8salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another
12.9schedule, whenever the existence of such isomers, esters, ethers and salts is possible
12.10within the specific chemical designation:
12.11(1) alfentanil;
12.12(2) alphaprodine;
12.13(3) anileridine;
12.14(4) bezitramide;
12.15(5) bulk dextropropoxyphene (nondosage forms);
12.16(6) carfentanil;
12.17(7) dihydrocodeine;
12.18(8) dihydromorphinone;
12.19(9) diphenoxylate;
12.20(10) fentanyl;
12.21(11) isomethadone;
12.22(12) levo-alpha-acetylmethadol (LAAM) levomethorphan;
12.23(13) levorphanol;
12.24(14) metazocine;
12.25(15) methadone;
12.26(16) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
12.27(17) moramide - intermediate, 2-methyl-3-morpholino-1,
12.281-diphenyl-propane-carboxylic acid;
12.29(18) pethidine;
12.30(19) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
12.31(20) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
12.32(21) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
12.33(22) phenazocine;
12.34(23) piminodine;
12.35(24) racemethorphan;
12.36(25) racemorphan;
13.1(26) remifentanil;
13.2(27) sufentanil;
13.3(28) tapentadol.
13.4(3) (d) Unless specifically excepted or unless listed in another schedule, any
13.5material, compound, mixture, or preparation which contains any quantity of the following
13.6substances having a stimulant effect on the central nervous system:
13.7(a) (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
13.8(b) (2) methamphetamine, its salts, isomers, and salts of its isomers;
13.9(c) (3) phenmetrazine and its salts;
13.10(d) (4) methylphenidate;
13.11(5) lisdexamfetamine.
13.12(4) (e) Unless specifically excepted or unless listed in another schedule, any
13.13material, compound, mixture, or preparation which contains any quantity of the following
13.14substances having a depressant effect on the central nervous system, including its salts,
13.15isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of
13.16isomers is possible within the specific chemical designation:
13.17(a) methaqualone
13.18(b) (1) amobarbital;
13.19(2) glutethimide;
13.20(c) (3) secobarbital;
13.21(d) (4) pentobarbital;
13.22(e) (5) phencyclidine;
13.23(f) (6) phencyclidine immediate precursors:
13.24(i) 1-phenylcyclohexylamine;
13.25(ii) 1-piperidinocyclohexanecarbonitrile;
13.26(7) phenylacetone.
13.27(f) Hallucinogenic substances: nabilone.
13.28    Subd. 4. Schedule III. The following items are listed in (a) Schedule III: consists of
13.29the substances listed in this subdivision.
13.30(1) Any material, compound, mixture, or preparation which contains any quantity of
13.31Amphetamine, its salts, optical isomers, and salts of its optical isomers; Phenmetrazine
13.32and its salts; Methamphetamine, its salts, isomers, and salts of isomers; Methylphenidate;
13.33and which is required by federal law to be labeled with the symbol prescribed by 21 Code
13.34of Federal Regulations Section 1302.03 and in effect on February 1, 1976 designating that
13.35the drug is listed as a Schedule III controlled substance under federal law. (b) Stimulants.
13.36Unless specifically excepted or unless listed in another schedule, any material, compound,
14.1mixture, or preparation which contains any quantity of the following substances having
14.2a potential for abuse associated with a stimulant effect on the central nervous system,
14.3including its salts, isomers, and salts of such isomers whenever the existence of such salts,
14.4isomers, and salts of isomers is possible within the specific chemical designation:
14.5(1) benzphetamine;
14.6(2) chlorphentermine;
14.7(3) clortermine;
14.8(4) phendimetrazine.
14.9(2) (c) Depressants. Unless specifically excepted or unless listed in another schedule,
14.10any material, compound, mixture, or preparation which contains any quantity of the
14.11following substances having a potential for abuse associated with a depressant effect on
14.12the central nervous system:
14.13(a) (1) any compound, mixture, or preparation containing amobarbital, secobarbital,
14.14pentobarbital or any salt thereof and one or more other active medicinal ingredients which
14.15are not listed in any schedule.;
14.16(b) (2) any suppository dosage form containing amobarbital, secobarbital,
14.17pentobarbital, or any salt of any of these drugs and approved by the food and drug
14.18administration for marketing only as a suppository.;
14.19(c) (3) any substance which contains any quantity of a derivative of barbituric acid,
14.20or any salt of a derivative of barbituric acid, except those substances which are specifically
14.21listed in other schedules: Chlorhexadol; Glutethimide; Lysergic acid; Lysergic acid amide;
14.22Methyprylon; Sulfondiethylmethane; Sulfonethylmethane; Sulfonmethane.;
14.23(d) Gamma hydroxybutyrate, any salt, compound, derivative, or preparation of
14.24gamma hydroxybutyrate, including any isomers, esters, and ethers and salts of isomers,
14.25esters, and ethers of gamma hydroxybutyrate whenever the existence of such isomers,
14.26esters, and salts is possible within the specific chemical designation. (4) any drug product
14.27containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers,
14.28for which an application is approved under section 505 of the federal Food, Drug, and
14.29Cosmetic Act;
14.30(5) any of the following substances:
14.31(i) chlorhexadol;
14.32(ii) ketamine, its salts, isomers and salts of isomers;
14.33(iii) lysergic acid;
14.34(iv) lysergic acid amide;
14.35(v) methyprylon;
14.36(vi) sulfondiethylmethane;
15.1(vii) sulfonenthylmethane;
15.2(viii) sulfonmethane;
15.3(ix) tiletamine and zolazepam and any salt thereof;
15.4(x) embutramide.
15.5(3) Any material, compound, mixture, or preparation which contains any quantity of
15.6the following substances having a potential for abuse associated with a stimulant effect on
15.7the central nervous system:
15.8(a) Benzphetamine
15.9(b) Chlorphentermine
15.10(c) Clortermine
15.11(d) Mazindol
15.12(e) Phendimetrazine.
15.13(4) (d) Nalorphine.
15.14(5) Any material, compound, mixture, or preparation containing limited quantities
15.15of any of the following narcotic drugs, or any salts thereof (e) Narcotic drugs. Unless
15.16specifically excepted or unless listed in another schedule, any material, compound,
15.17mixture, or preparation containing any of the following narcotic drugs, or their salts
15.18calculated as the free anhydrous base or alkaloid, in limited quantities as follows:
15.19(a) (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
15.20milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
15.21of opium.;
15.22(b) (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90
15.23milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
15.24therapeutic amounts.;
15.25(c) (3) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or
15.26not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an
15.27isoquinoline alkaloid of opium.;
15.28(d) (4) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
15.29more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
15.30in recognized therapeutic amounts.;
15.31(e) (5) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more
15.32than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
15.33recognized therapeutic amounts.;
15.34(f) (6) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
15.35than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
15.36recognized therapeutic amounts.;
16.1(g) (7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
16.2or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic
16.3ingredients in recognized therapeutic amounts.;
16.4(h) (8) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
16.5with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.;
16.6(6) (f) Anabolic steroids, which and human growth hormone.
16.7(1) Anabolic steroids, for purposes of this subdivision, means any drug or
16.8hormonal substance, chemically and pharmacologically related to testosterone, other
16.9than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes:
16.10androstanediol; androstanedione; androstenediol; androstenedione; bolasterone;
16.11boldenone; calusterone; chlorotestosterone; chorionic gonadotropin; clostebol;
16.12dehydrochloromethyltestosterone; (triangle)1-dihydrotestosterone; 4-dihydrotestosterone;
16.13drostanolone; ethylestrenol; fluoxymesterone; formebolone; furazabol; human
16.14growth hormones; 13b-ethyl-17a-hydroxygon-4-en-3-one; 4-hydroxytestosterone;
16.154-hydroxy-19-nortestosterone; mestanolone; mesterolone; methandienone;
16.16methandranone; methandriol; methandrostenolone; methenolone; 17a-methyl-3b,
16.1717b-dihydroxy-5a-androstane; 17a-methyl-3a, 17b-dihydroxy-5a-androstane;
16.1817a-methyl-3b, 17b-dihydroxyandrost-4-ene; 17a-methyl-4-hydroxynandrolone;
16.19methyldienolone; methyltrienolone; methyltestosterone; mibolerone;
16.2017a-methyl-(triangle)1-dihydrotestosterone; nandrolone; nandrolone phenpropionate;
16.21norandrostenediol; norandrostenedione; norbolethone; norclostebol; norethandrolone;
16.22normethandrolone; oxandrolone; oxymesterone; oxymetholone; stanolone; stanozolol;
16.23stenbolone; testolactone; testosterone; testosterone propionate; tetrahydrogestrinone;
16.24trenbolone; and any salt, ester, or ether of a drug or substance described in this paragraph.
16.25(i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
16.26(ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
16.27(iii) androstanedione (5[alpha]-androstan-3,17-dione);
16.28(iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene;
16.29(v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
16.30(vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
16.31(vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
16.32(viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);
16.33(ix) 4-androstenedione (androst-4-en-3,17-dione);
16.34(x) 5-androstenedione (androst-5-en-3,17-dione);
16.35(xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
16.36(xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);
17.1(xiii) boldione (androsta-1,4-diene-3,17-dione);
17.2(xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
17.3(xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);
17.4(xvi) dehydrochloromethyltestosterone
17.5(4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);
17.6(xvii) desoxymethyltestosterone
17.7(17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);
17.8(xviii) [delta]1-dihydrotestosterone-
17.9(17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
17.10(xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);
17.11(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);
17.12(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);
17.13(xxii) fluoxymesterone
17.14(9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);
17.15(xxiii) formebolone
17.16(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
17.17(xxiv) furazabol
17.18(17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta]
17.19-hydroxygon-4-en-3-one;
17.20(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
17.21(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
17.22(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
17.23(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
17.24(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
17.25(xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
17.26(xxxi) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
17.27(xxxii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
17.28(xxxiii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
17.29(xxxiv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
17.30(xxxv) 17[alpha]-methyl-4-hydroxynandrolone
17.31(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
17.32(xxxvi) methyldienolone
17.33(17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
17.34(xxxvii) methyltrienolone
17.35(17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
18.1(xxxviii) methyltestosterone
18.2(17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);
18.3(xxxix) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
18.4(xl) 17[alpha]-methyl-[delta]1-dihydrotestosterone
18.5(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
18.6(xli) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
18.7(xlii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;
18.8(xliii) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol
18.9(3[beta],17[beta]-dihydroxyestr-5-ene;
18.10(xliv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
18.11(xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
18.12(xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
18.13(xlvii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
18.14(xlviii) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
18.15(xlix) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
18.16(l) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
18.17(li) oxandrolone
18.18(17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
18.19(lii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
18.20(liii) oxymetholone
18.21(17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
18.22(liv) stanozolol
18.23(17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
18.24(lv) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
18.25(lvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
18.26lactone);
18.27(lvii) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
18.28(lviii) tetrahydrogestrinone
18.29(13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
18.30(lix) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
18.31(lx) any salt, ester, or ether of a drug or substance described in this paragraph.
18.32Anabolic steroids are not included if they are: (i) (A) expressly intended for administration
18.33through implants to cattle or other nonhuman species; and (ii) (B) approved by the United
18.34States Food and Drug Administration for that use.;
18.35(2) Human growth hormones.
19.1(g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and
19.2encapsulated in a soft gelatin capsule in a United States Food and Drug Administration
19.3approved product.
19.4(h) Any material, compound, mixture, or preparation containing the following
19.5narcotic drug or its salt: buprenorphine.
19.6    Subd. 5. Schedule IV. The following items are listed in Schedule IV: Barbital;
19.7Butorphanol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clonazepam;
19.8Clorazepate; Diazepam; Diethylpropion; Ethchlorvynol; Ethinamate; Fenfluramine;
19.9Flurazepam; Mebutamate; Methohexital; Meprobamate except when in combination with
19.10the following drugs in the following or lower concentrations: conjugated estrogens, 0.4
19.11mg; tridihexethyl chloride, 25mg; pentaerythritol tetranitrate, 20 mg; Methylphenobarbital;
19.12Oxazepam; Paraldehyde; Pemoline; Petrichloral; Phenobarbital; and Phentermine (a)
19.13Schedule IV consists of the substances listed in this subdivision.
19.14(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
19.15any material, compound, mixture, or preparation containing any of the following narcotic
19.16drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
19.17as follows:
19.18(1) not more than one milligram of difenoxin and not less than 25 micrograms of
19.19atropine sulfate per dosage unit;
19.20(2) dextropropoxyphene (Darvon and Darvocet).
19.21(c) Depressants. Unless specifically excepted or unless listed in another schedule,
19.22any material, compound, mixture, or preparation containing any quantity of the following
19.23substances, including its salts, isomers, and salts of isomers whenever the existence of the
19.24salts, isomers, and salts of isomers is possible:
19.25(1) alprazolam;
19.26(2) barbital;
19.27(3) bromazepam;
19.28(4) camazepam;
19.29(5) carisoprodol;
19.30(6) chloral betaine;
19.31(7) chloral hydrate;
19.32(8) chlordiazepoxide;
19.33(9) clobazam;
19.34(10) clonazepam;
19.35(11) clorazepate;
19.36(12) clotiazepam;
20.1(13) cloxazolam;
20.2(14) delorazepam;
20.3(15) diazepam;
20.4(16) dichloralphenazone;
20.5(17) estazolam;
20.6(18) ethchlorvynol;
20.7(19) ethinamate;
20.8(20) ethyl loflazepate;
20.9(21) fludiazepam;
20.10(22) flurazepam;
20.11(23) halazepam;
20.12(24) haloxazolam;
20.13(25) ketazolam;
20.14(26) loprazolam;
20.15(27) lorazepam;
20.16(28) lormetazepam mebutamate;
20.17(29) medazepam;
20.18(30) meprobamate;
20.19(31) methohexital;
20.20(32) methylphenobarbital;
20.21(33) midazolam;
20.22(34) nimetazepam;
20.23(35) nitrazepamnordiazepam;
20.24(36) oxazepam;
20.25(37) oxazolam;
20.26(38) paraldehydepetrichloral;
20.27(39) phenobarbital;
20.28(40) pinazepam;
20.29(41) prazepam;
20.30(42) quazepam;
20.31(43) temazepam;
20.32(44) tetrazepam;
20.33(45) triazolam;
20.34(46) zaleplon;
20.35(47) zolpidem;
20.36(48) zopiclone.
21.1(d) Any material, compound, mixture, or preparation which contains any quantity of
21.2the following substance including its salts, isomers, and salts of such isomers, whenever
21.3the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.
21.4(e) Stimulants. Unless specifically excepted or unless listed in another schedule,
21.5any material, compound, mixture, or preparation which contains any quantity of the
21.6following substances having a stimulant effect on the central nervous system, including its
21.7salts, isomers, and salts of isomers:
21.8(1) cathine (norpseudoephedrine);
21.9(2) diethylpropion;
21.10(3) fencamfamine;
21.11(4) fenproporex;
21.12(5) mazindol;
21.13(6) mefenorex;
21.14(7) modafinil;
21.15(8) pemoline (including organometallic complexes and chelates thereof);
21.16(9) phentermine;
21.17(10) pipradol;
21.18(11) sibutramine;
21.19(12) SPA (1-dimethylamino-1,2-diphenylethane).
21.20    Subd. 6. Schedule V; restrictions on methamphetamine precursor drugs. (a) As
21.21used in this subdivision, the following terms have the meanings given:
21.22(1) "methamphetamine precursor drug" means any compound, mixture, or
21.23preparation intended for human consumption containing ephedrine or pseudoephedrine as
21.24its sole active ingredient or as one of its active ingredients; and
21.25(2) "over-the-counter sale" means a retail sale of a drug or product but does not
21.26include the sale of a drug or product pursuant to the terms of a valid prescription.
21.27(b) The following items are listed in Schedule V:
21.28(1) any compound, mixture, or preparation containing any of the following limited
21.29quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal
21.30ingredients in sufficient proportion to confer upon the compound, mixture or preparation
21.31valuable medicinal qualities other than those possessed by the narcotic drug alone:
21.32(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
21.33grams;
21.34(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
21.35grams;
22.1(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms
22.2of atropine sulfate per dosage unit; or
22.3(iv) not more than 15 milligrams of anhydrous morphine per 100 milliliters or per
22.4100 grams; and 100 milligrams of opium per 100 milliliters or per 100 grams; or
22.5(v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of
22.6atropine sulfate per dosage unit.
22.7(2) Stimulants. Unless specifically exempted or excluded or unless listed in another
22.8schedule, any material, compound, mixture, or preparation that contains any quantity of
22.9the following substance having a stimulant effect on the central nervous system, including
22.10its salts, isomers, and salts of isomers: pyrovalerone.
22.11(3) Depressants. Unless specifically exempted or excluded or unless listed in another
22.12schedule, any material, compound, mixture, or preparation that contains any quantity
22.13of the following substance having a depressant effect on the central nervous system,
22.14including its salts, isomers, and salts of isomers:
22.15(i) pregabalin;
22.16(ii) lacosamide.
22.17(2) (4) Any compound, mixture, or preparation containing ephedrine or
22.18pseudoephedrine as its sole active ingredient or as one of its active ingredients.
22.19(c) No person may sell in a single over-the-counter sale more than two packages
22.20of a methamphetamine precursor drug or a combination of methamphetamine precursor
22.21drugs or any combination of packages exceeding a total weight of six grams, calculated as
22.22the base.
22.23(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:
22.24(1) packages containing not more than a total of three grams of one or
22.25more methamphetamine precursor drugs, calculated in terms of ephedrine base or
22.26pseudoephedrine base; or
22.27(2) for nonliquid products, sales in blister packs, where each blister contains not
22.28more than two dosage units, or, if the use of blister packs is not technically feasible, sales
22.29in unit dose packets or pouches.
22.30(e) A business establishment that offers for sale methamphetamine precursor drugs
22.31in an over-the-counter sale shall ensure that all packages of the drugs are displayed
22.32behind a checkout counter where the public is not permitted and are offered for sale only
22.33by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The
22.34establishment shall ensure that the person making the sale requires the buyer:
22.35(1) to provide photographic identification showing the buyer's date of birth; and
23.1(2) to sign a written or electronic document detailing the date of the sale, the name
23.2of the buyer, and the amount of the drug sold.
23.3A document described under clause (2) must be retained by the establishment for
23.4at least three years and must at all reasonable times be open to the inspection of any
23.5law enforcement agency.
23.6Nothing in this paragraph requires the buyer to obtain a prescription for the drug's
23.7purchase.
23.8(f) No person may acquire through over-the-counter sales more than six grams of
23.9methamphetamine precursor drugs, calculated as the base, within a 30-day period.
23.10(g) No person may sell in an over-the-counter sale a methamphetamine precursor
23.11drug to a person under the age of 18 years. It is an affirmative defense to a charge under
23.12this paragraph if the defendant proves by a preponderance of the evidence that the
23.13defendant reasonably and in good faith relied on proof of age as described in section
23.14340A.503, subdivision 6 .
23.15(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of
23.16a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to
23.17payment of a fine of not more than $1,000, or both.
23.18(i) An owner, operator, supervisor, or manager of a business establishment that
23.19offers for sale methamphetamine precursor drugs whose employee or agent is convicted of
23.20or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal
23.21penalties for violating any of those paragraphs if the person:
23.22(1) did not have prior knowledge of, participate in, or direct the employee or agent to
23.23commit the violation; and
23.24(2) documents that an employee training program was in place to provide the
23.25employee or agent with information on the state and federal laws and regulations regarding
23.26methamphetamine precursor drugs.
23.27(j) Any person employed by a business establishment that offers for sale
23.28methamphetamine precursor drugs who sells such a drug to any person in a suspicious
23.29transaction shall report the transaction to the owner, supervisor, or manager of the
23.30establishment. The owner, supervisor, or manager may report the transaction to local law
23.31enforcement. A person who reports information under this subdivision in good faith is
23.32immune from civil liability relating to the report.
23.33(k) Paragraphs (b) to (j) do not apply to:
23.34(1) pediatric products labeled pursuant to federal regulation primarily intended for
23.35administration to children under 12 years of age according to label instructions;
24.1(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as
24.2being manufactured in a manner that prevents the drug from being used to manufacture
24.3methamphetamine;
24.4(3) methamphetamine precursor drugs in gel capsule or liquid form; or
24.5(4) compounds, mixtures, or preparations in powder form where pseudoephedrine
24.6constitutes less than one percent of its total weight and is not its sole active ingredient.
24.7(l) The Board of Pharmacy, in consultation with the Department of Public Safety,
24.8shall certify methamphetamine precursor drugs that meet the requirements of paragraph
24.9(k), clause (2), and publish an annual listing of these drugs.
24.10(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy
24.11pursuant to sections 151.42 to 151.51 and registered with and regulated by the United
24.12States Drug Enforcement Administration are exempt from the methamphetamine precursor
24.13drug storage requirements of this section.
24.14(n) This section preempts all local ordinances or regulations governing the sale
24.15by a business establishment of over-the-counter products containing ephedrine or
24.16pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.
24.17    Subd. 7. Board of Pharmacy; regulation of substances. The Board of Pharmacy
24.18is authorized to regulate and define additional substances which contain quantities of a
24.19substance possessing abuse potential in accordance with the following criteria:
24.20(1) The Board of Pharmacy shall place a substance in Schedule I if it finds that the
24.21substance has: A high potential for abuse, no currently accepted medical use in the United
24.22States, and a lack of accepted safety for use under medical supervision.
24.23(2) The Board of Pharmacy shall place a substance in Schedule II if it finds that the
24.24substance has: A high potential for abuse, currently accepted medical use in the United
24.25States, or currently accepted medical use with severe restrictions, and that abuse may lead
24.26to severe psychological or physical dependence.
24.27(3) The Board of Pharmacy shall place a substance in Schedule III if it finds that the
24.28substance has: A potential for abuse less than the substances listed in Schedules I and II,
24.29currently accepted medical use in treatment in the United States, and that abuse may lead
24.30to moderate or low physical dependence or high psychological dependence.
24.31(4) The Board of Pharmacy shall place a substance in Schedule IV if it finds that
24.32the substance has: A low potential for abuse relative to the substances in Schedule III,
24.33currently accepted medical use in treatment in the United States, and that abuse may lead
24.34to limited physical dependence or psychological dependence relative to the substances in
24.35Schedule III.
25.1(5) The Board of Pharmacy shall place a substance in Schedule V if it finds that the
25.2substance has: A low potential for abuse relative to the substances listed in Schedule IV,
25.3currently accepted medical use in treatment in the United States, and limited physical
25.4dependence and/or psychological dependence liability relative to the substances listed
25.5in Schedule IV.
25.6    Subd. 8. Add, delete, or reschedule substances. The state Board of Pharmacy may,
25.7by rule, add substances to or delete or reschedule substances listed in this section. The
25.8Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as
25.9provided in subdivision 12.
25.10In making a determination regarding a substance, the Board of Pharmacy shall
25.11consider the following: The actual or relative potential for abuse, the scientific evidence
25.12of its pharmacological effect, if known, the state of current scientific knowledge
25.13regarding the substance, the history and current pattern of abuse, the scope, duration,
25.14and significance of abuse, the risk to public health, the potential of the substance to
25.15produce psychic or physiological dependence liability, and whether the substance is an
25.16immediate precursor of a substance already controlled under this section. The state Board
25.17of Pharmacy may include any nonnarcotic drug authorized by federal law for medicinal
25.18use in a schedule only if such drug must, under either federal or state law or rule, be
25.19sold only on prescription.
25.20    Subd. 8a. Methamphetamine precursors. The State Board of Pharmacy may,
25.21by order, require that nonprescription ephedrine or pseudophedrine products sold in
25.22gel capsule or liquid form be subject to the sale restrictions established in subdivision
25.236 for methamphetamine precursor drugs, if the board concludes that ephedrine or
25.24pseudophedrine products in gel capsule or liquid form can be used to manufacture
25.25methamphetamine. In assessing the need for an order under this subdivision, the board
25.26shall consult at least annually with the advisory council on controlled substances, the
25.27commissioner of public safety, and the commissioner of health.
25.28    Subd. 9. Except substances by rule. The state Board of Pharmacy may by rule
25.29except any compound, mixture, or preparation containing any stimulant or depressant
25.30substance listed in subdivision 4, clauses (1) and (2) paragraphs (b) and (c), or in
25.31subdivisions 5 and 6 from the application of all or any part of this chapter, if the
25.32compound, mixture, or preparation contains one or more active medicinal ingredients not
25.33having a stimulant or depressant effect on the central nervous system; provided, that
25.34such admixtures shall be included therein in such combinations, quantity, proportion,
25.35or concentration as to vitiate the potential for abuse of the substances which do have a
25.36stimulant or depressant effect on the central nervous system.
26.1    Subd. 10. Dextromethorphan. Dextromethorphan shall not be deemed to be
26.2included in any schedule by reason of the enactment of Laws 1971, chapter 937, unless
26.3controlled pursuant to the foregoing provisions of this section.
26.4    Subd. 12. Coordination of controlled substance regulation with federal law and
26.5state statute. If any substance is designated, rescheduled, or deleted as a controlled
26.6substance under federal law and notice thereof is given to the state Board of Pharmacy, the
26.7state Board of Pharmacy shall similarly control the substance under this chapter, after the
26.8expiration of 30 days from publication in the Federal Register of a final order designating
26.9a substance as a controlled substance or rescheduling or deleting a substance. Such order
26.10shall be filed with the secretary of state. If within that 30-day period, the state Board of
26.11Pharmacy objects to inclusion, rescheduling, or deletion, it shall publish the reasons for
26.12objection and afford all interested parties an opportunity to be heard. At the conclusion of
26.13the hearing, the state Board of Pharmacy shall publish its decision, which shall be subject
26.14to the provisions of chapter 14.
26.15In exercising the authority granted by this chapter, the state Board of Pharmacy shall
26.16be subject to the provisions of chapter 14. The state Board of Pharmacy shall provide
26.17copies of any proposed rule under this chapter to the advisory council on controlled
26.18substances at least 30 days prior to any hearing required by section 14.14, subdivision 1.
26.19The state Board of Pharmacy shall consider the recommendations of the advisory council
26.20on controlled substances, which may be made prior to or at the hearing.
26.21The state Board of Pharmacy shall annually submit a report to the legislature on or
26.22before December 1 that specifies what changes the board made to the controlled substance
26.23schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in
26.24the preceding 12 months. The report must include specific recommendations for amending
26.25the controlled substance schedules contained in subdivisions 2 to 6, so that they conform
26.26with the controlled substance schedules maintained by the board in Minnesota Rules,
26.27parts 6800.4210 to 6800.4250.
26.28    Subd. 13. Implementation study. Annually, the state Board of Pharmacy shall study
26.29the implementation of this chapter in relation to the problems of drug abuse in Minnesota.
26.30EFFECTIVE DATE.This section is effective August 1, 2012, and applies to crimes
26.31committed on or after that date.

26.32    Sec. 2. Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6, is
26.33amended to read:
27.1    Subd. 6. Sale or possession of synthetic cannabinoids. (a) As used in this
27.2subdivision, "synthetic cannabinoid" includes any substance included in section 152.02,
27.3subdivision 2, paragraph (h), clause (7) (3).
27.4(b) A person who unlawfully sells a synthetic cannabinoid for no remuneration is
27.5guilty of a gross misdemeanor.
27.6(c) A person who unlawfully sells any amount of a synthetic cannabinoid is guilty of
27.7a gross misdemeanor felony and if convicted may be sentenced to imprisonment for not
27.8more than five years or to payment of a fine of not more than $10,000, or both.
27.9(c) (d) A person who unlawfully possesses any amount of a synthetic cannabinoid is
27.10guilty of a misdemeanor.
27.11(d) (e) Notwithstanding any contrary provision in sections 152.021 to 152.025, this
27.12subdivision describes the exclusive penalties for the sale and possession of synthetic
27.13cannabinoid.
27.14EFFECTIVE DATE.This section is effective August 1, 2012, and applies to crimes
27.15committed on or after that date.

27.16    Sec. 3. Minnesota Statutes 2010, section 152.18, subdivision 1, is amended to read:
27.17    Subdivision 1. Deferring prosecution for certain first time drug offenders. If
27.18any person who has not previously participated in or completed a diversion program
27.19authorized under section 401.065 or who has not previously been placed on probation
27.20without a judgment of guilty and thereafter been discharged from probation under
27.21this section is found guilty of a violation of section 152.024, subdivision 2, 152.025,
27.22subdivision 2 , or 152.027, subdivision 2, 3, or 4, or 6, paragraph (d), for possession of a
27.23controlled substance, after trial or upon a plea of guilty, and the court determines that the
27.24violation does not qualify as a subsequent controlled substance conviction under section
27.25152.01, subdivision 16a , the court may, without entering a judgment of guilty and with the
27.26consent of the person, defer further proceedings and place the person on probation upon
27.27such reasonable conditions as it may require and for a period, not to exceed the maximum
27.28sentence provided for the violation. The court may give the person the opportunity to
27.29attend and participate in an appropriate program of education regarding the nature and
27.30effects of alcohol and drug abuse as a stipulation of probation. Upon violation of a
27.31condition of the probation, the court may enter an adjudication of guilt and proceed as
27.32otherwise provided. The court may, in its discretion, dismiss the proceedings against the
27.33person and discharge the person from probation before the expiration of the maximum
27.34period prescribed for the person's probation. If during the period of probation the person
27.35does not violate any of the conditions of the probation, then upon expiration of the period
28.1the court shall discharge the person and dismiss the proceedings against that person.
28.2Discharge and dismissal under this subdivision shall be without court adjudication of guilt,
28.3but a not public record of it shall be retained by the Bureau of Criminal Apprehension
28.4for the purpose of use by the courts in determining the merits of subsequent proceedings
28.5against the person. The not public record may also be opened only upon court order for
28.6purposes of a criminal investigation, prosecution, or sentencing. Upon request by law
28.7enforcement, prosecution, or corrections authorities, the bureau shall notify the requesting
28.8party of the existence of the not public record and the right to seek a court order to open it
28.9pursuant to this section. The court shall forward a record of any discharge and dismissal
28.10under this subdivision to the bureau which shall make and maintain the not public record
28.11of it as provided under this subdivision. The discharge or dismissal shall not be deemed a
28.12conviction for purposes of disqualifications or disabilities imposed by law upon conviction
28.13of a crime or for any other purpose.
28.14For purposes of this subdivision, "not public" has the meaning given in section
28.1513.02, subdivision 8a .
28.16EFFECTIVE DATE.This section is effective August 1, 2012, and applies to crimes
28.17committed on or after that date.